المؤلفون: Stefania Paolini, Francesco Barbato, Sarah Parisi, Chiara Sartor, Valentina Robustelli, Giovanni Marconi, Nicoletta Testoni, Antonio Curti, Mario Arpinati, Gianluca Cristiano, Michele Cavo, Simona Soverini, Jacopo Nanni, Elisabetta Zappone, Gabriella Chirumbolo, Cristina Papayannidis, Francesca Bonifazi, Carolina Terragna, Alida Dominietto

المساهمون: Papayannidis C., Sartor C., Dominietto A., Zappone E., Arpinati M., Marconi G., Cristiano G., Nanni J., Parisi S., Barbato F., Paolini S., Soverini S., Terragna C., Robustelli V., Testoni N., Chirumbolo G., Curti A., Cavo M., Bonifazi F.

المصدر: Hematological Oncology. 39:580-583

مصطلحات موضوعية: Adult, Male, Cancer Research, Adolescent, Prognosi, Lymphoblastic Leukemia, donor lymphocyte infusion, acute lymphoblastic leukemia, Donor lymphocyte infusion, Follow-Up Studie, Young Adult, Antineoplastic Agents, Immunological, Retrospective Studie, stem cell transplant, medicine, Humans, Inotuzumab Ozogamicin, Retrospective Studies, Salvage Therapy, Inotuzumab ozogamicin, business.industry, Hematology, General Medicine, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Prognosis, Combined Modality Therapy, Survival Rate, Oncology, Lymphocyte Transfusion, Cancer research, Female, Neoplasm Recurrence, Local, Stem cell, business, Follow-Up Studies, Human, Stem Cell Transplantation, medicine.drug

وصف الملف: STAMPA

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fcec9b82ad040c7e50d330235ff1549Test
https://doi.org/10.1002/hon.2886Test

المؤلفون: Sarah Parisi, Chiara Sartor, Gianluca Cristiano, Antonio Curti, Annalisa Talami, Emanuela Ottaviani, Jayakumar Vadakekolathu, Matteo Olivi, Sarah Wagner, Simone Ragaini, Michele Cavo, Cristina Papayannidis, Giovanni Marconi, Stefania Paolini, Jacopo Nanni, Sergio Rutella, Darina Očadlíková, Giulia Corradi, Marilena Ciciarello

المصدر: Blood Advances

مصطلحات موضوعية: Inflammation, Immune tolerance, Transcriptome, Immune system, Semaphorin, Interferon, hemic and lymphatic diseases, medicine, Immune Tolerance, Tumor Microenvironment, Humans, Indoleamine-Pyrrole 2,3,-Dioxygenase, neoplasms, Myeloid Neoplasia, business.industry, Myeloid leukemia, Hematology, Prognosis, Leukemia, Myeloid, Acute, medicine.anatomical_structure, Cancer research, Bone marrow, medicine.symptom, business, medicine.drug

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b122fd8347e3a6c8645b078ac603ba7fTest
http://europepmc.org/articles/PMC8753212Test

المؤلفون: Alessia Tieghi, Alessandra D'Addio, Florian H. Heidel, Roberto Latagliata, Elisa Bossi, Francesco Cavazzini, Giulia Benevolo, Nicola Vianelli, Michele Cavo, Roberto M. Lemoli, Mauro Krampera, Massimo Breccia, Massimiliano Bonifacio, Gianni Binotto, Antonio Cuneo, Giovanni Caocci, Daniela Bartoletti, Mario Tiribelli, Ida Carmosino, Lucia Catani, Giuseppe Auteri, Francesco Lanza, Giuseppe A. Palumbo, Nicola Polverelli, Francesca Palandri, Micaela Bergamaschi, Monica Crugnola, Elena Maria Elli

المساهمون: Benevolo G., Elli E.M., Bartoletti D., Latagliata R., Tiribelli M., Heidel F.H., Cavazzini F., Bonifacio M., Crugnola M., Binotto G., D'Addio A., Tieghi A., Bergamaschi M., Caocci G., Polverelli N., Bossi E., Auteri G., Carmosino I., Catani L., Cuneo A., Krampera M., Lanza F., Lemoli R.M., Vianelli N., Breccia M., Palumbo G.A., Cavo M., Palandri F.

المصدر: Hematological Oncology. 39:409-418

مصطلحات موضوعية: Male, Cancer Research, Comorbidity, Overweight, Primary Myelofibrosi, 0302 clinical medicine, Retrospective Studie, Risk Factors, body mass index, cancer, Charlson comorbidity index, outcome, polycythemia vera, thrombotic risk, 80 and over, Cumulative incidence, Aged, 80 and over, Incidence, Incidence (epidemiology), Hazard ratio, Hematology, General Medicine, Middle Aged, Oncology, 030220 oncology & carcinogenesis, Thrombosi, Female, Underweight, medicine.symptom, Human, Adult, medicine.medical_specialty, NO, Follow-Up Studie, 03 medical and health sciences, Internal medicine, medicine, Humans, Aged, Retrospective Studies, business.industry, Risk Factor, Thrombosis, Retrospective cohort study, medicine.disease, Follow-Up Studies, Polycythemia Vera, Primary Myelofibrosis, Body Mass Index, Body Mass Index, Cancer, Charlson Comorbidity Index, Outcome, Polycythemia Vera, Thrombotic risk, business, Body mass index, 030215 immunology

وصف الملف: ELETTRONICO

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa3939263de47b0f932025c0ddc18dfcTest
https://doi.org/10.1002/hon.2843Test

المؤلفون: Hani Hassoun, Jacob P. Laubach, Jan S. Moreb, Sara Thuresson, Paula Rodriguez-Otero, Marcus Thuresson, Michele Cavo, Albert Oriol, Maria-Victoria Mateos, Joan Bladé, John W. Hiemenz, Adrian Alegre, Amitabha Mazumder, Horizon (Op ) Investigators, Kenneth C. Anderson, Omar Nadeem, Johan Harmenberg, Nicolaas A Bakker, Xavier Leleu, Alessandra Larocca, Christopher Maisel, Paul G. Richardson, Agne Paner, Anastasios Raptis, Cyrille Touzeau, Catriona Byrne

المساهمون: Harvard Medical School [Boston] (HMS), Hospital Universitari Germans Trias I Pujol [Badalona], Università degli studi di Torino = University of Turin (UNITO), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), University of Bologna/Università di Bologna, Clínica Universidad de Navarra [Pamplona], Centre hospitalier universitaire de Poitiers (CHU Poitiers), University of Florida [Gainesville] (UF), Memorial Sloane Kettering Cancer Center [New York], Regulation of Bcl2 and p53 Networks in Multiple Myeloma and Mantle Cell Lymphoma (CRCINA-ÉQUIPE 10), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Université d'Angers (UA), Université de Nantes (UN), Site de Recherche Intégrée sur le Cancer [Nantes] (SIRIC), Centre hospitalier universitaire de Nantes (CHU Nantes), SIRIC ILIAD [Angers, Nantes], Hospital Universitario Quironsalud, Rush University Medical Center [Chicago], Baylor Scott & White Charles A. Sammons Cancer Center [Dallas, TX, USA], Oncology Institute of Hope and Innovation [Glendale, CA, USA] (OIHI), University of Pittsburgh School of Medicine, Pennsylvania Commonwealth System of Higher Education (PCSHE), Novant Health Forsyth Medical Center [Winston-Salem, NC, USA] (NHFMC), Oncopeptides AB [Stockholm, Sweden], Instituto de Investigación Biomédica de Salamanca [Salamanca, Spain] (IBSAL/CIC), HORIZON (OP-106) Investigators, Bernardo, Elizabeth, Università degli studi di Torino (UNITO), University of Bologna, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Richardson P.G., Oriol A., Larocca A., Blade J., Cavo M., Rodriguez-Otero P., Leleu X., Nadeem O., Hiemenz J.W., Hassoun H., Touzeau C., Alegre A., Paner A., Maisel C., Mazumder A., Raptis A., Moreb J.S., Anderson K.C., Laubach J.P., Thuresson S., Thuresson M., Byrne C., Harmenberg J., Bakker N.A., Mateos M.-V.

المصدر: Journal of Clinical Oncology
Journal of Clinical Oncology, 2021, 39 (7), pp.757-767. ⟨10.1200/JCO.20⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2021, 39 (7), pp.757-767. ⟨10.1200/JCO.20⟩
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

مصطلحات موضوعية: Adult, Male, Cancer Research, Time Factors, Time Factor, Phenylalanine, [SDV.CAN]Life Sciences [q-bio]/Cancer, Tumor cells, Drug resistance, Dexamethasone, 03 medical and health sciences, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Recurrence, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Neoplasm, Progression-free survival, Melphalan, Aged, 030304 developmental biology, Aged, 80 and over, 0303 health sciences, Antineoplastic Combined Chemotherapy Protocol, business.industry, Refractory Multiple Myeloma, Middle Aged, medicine.disease, Progression-Free Survival, United States, 3. Good health, Europe, Clinical trial, Oncology, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Disease Progression, Cancer research, Female, Multiple Myeloma, business, Human, Conjugate, medicine.drug

وصف الملف: application/pdf; STAMPA

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79bb7c110aefa09f245d7dfe112c3ba4Test
https://doi.org/10.1200/jco.20.02259Test

المؤلفون: Jesús F. San-Miguel, U. Mey, Mario Boccadoro, Thierry Facon, Roman Hájek, P. Moreau, M.V. Mateos, E. Terpos, M.A. Dimopoulos, Michele Cavo, Fredrik Schjesvold, H. Goldschmidt, Gordon Cook, Michel Delforge, Sonja Zweegman, H. Einsele, Pieter Sonneveld

المساهمون: Hematology, CCA - Cancer Treatment and quality of life, Dimopoulos M.A., Moreau P., Terpos E., Mateos M.V., Zweegman S., Cook G., Delforge M., Hajek R., Schjesvold F., Cavo M., Goldschmidt H., Facon T., Einsele H., Boccadoro M., San-Miguel J., Sonneveld P., Mey U.

المصدر: EHA Guidelines Committee & ESMO Guidelines Committee 2021, ' Multiple myeloma : EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † ', Annals of Oncology, vol. 32, no. 3, pp. 309-322 . https://doi.org/10.1016/j.annonc.2020.11.014Test
Annals of Oncology, 32(3), 309-322. Oxford University Press
Annals of Oncology, 32(3), 309-322. Elsevier Ltd.
Dimopoulos, M A, Moreau, P, Terpos, E, Mateos, M V, Zweegman, S, Cook, G, Delforge, M, Hájek, R, Schjesvold, F, Cavo, M, Goldschmidt, H, Facon, T, Einsele, H, Boccadoro, M, San-Miguel, J, Sonneveld, P & Mey, U 2021, ' Multiple Myeloma : EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up ', HemaSphere . https://doi.org/10.1097/HS9.0000000000000528Test
HemaSphere

مصطلحات موضوعية: Pediatrics, medicine.medical_specialty, MINIMAL RESIDUAL DISEASE, BORTEZOMIB, THERAPY, Follow-Up Studie, CONDITIONING REGIMEN, follow-up, ORAL IXAZOMIB, Medicine, Multiple myeloma, Societies, Medical, Science & Technology, treatment, INTERGROUPE FRANCOPHONE, business.industry, Follow up studies, STEM-CELL TRANSPLANTATION, Hematology, Guideline Article - Consensus based, medicine.disease, OPEN-LABEL, PHASE-III, Clinical Practice, multiple myeloma, diagnosi, Oncology, Diagnosis treatment, business, Life Sciences & Biomedicine, clinical practice guideline, prognosi, LENALIDOMIDE PLUS DEXAMETHASONE, Human

وصف الملف: application/pdf; Electronic-eCollection; STAMPA

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f60c3c6609190b33f4f46700bb41d85cTest
https://pure.eur.nl/en/publications/9ef136fc-4fcf-4dc0-ba1f-c56b9dd51cd7Test

المؤلفون: Michele Cavo, Ioannis Ntanasis-Stathopoulos, Charalampia Kyriakou, Brian G.M. Durie, Jesús F. San-Miguel, Fredrik Schjesvold, Philippe Moreau, Sonja Zweegman, Noopur Raje, Evangelos Terpos, Nikhil C. Munshi, Matthew T. Drake, Meletios A. Dimopoulos, Elena Zamagni, Suzanne Lentzsch, Niels Abildgaard, Jens Hillengass, Javier de la Rubia, Ramón García-Sanz

المساهمون: Terpos E., Zamagni E., Lentzsch S., Drake M.T., Garcia-Sanz R., Abildgaard N., Ntanasis-Stathopoulos I., Schjesvold F., de la Rubia J., Kyriakou C., Hillengass J., Zweegman S., Cavo M., Moreau P., San-Miguel J., Dimopoulos M.A., Munshi N., Durie B.G.M., Raje N.

المصدر: Terpos, E, Zamagni, E, Lentzsch, S, Drake, M T, García-Sanz, R, Abildgaard, N, Ntanasis-Stathopoulos, I, Schjesvold, F, de la Rubia, J, Kyriakou, C, Hillengass, J, Zweegman, S, Cavo, M, Moreau, P, San-Miguel, J, Dimopoulos, M A, Munshi, N, Durie, B G M, Raje, N & Bone Working Group of the International Myeloma Working Group 2021, ' Treatment of multiple myeloma-related bone disease : recommendations from the Bone Working Group of the International Myeloma Working Group ', The Lancet Oncology, vol. 22, no. 3, pp. e119-e130 . https://doi.org/10.1016/S1470-2045Test(20)30559-3
Bone Working Group of the International Myeloma Working Group 2021, ' Treatment of multiple myeloma-related bone disease : recommendations from the Bone Working Group of the International Myeloma Working Group ', The Lancet Oncology, vol. 22, no. 3, pp. e119-e130 . https://doi.org/10.1016/S1470-2045Test(20)30559-3

مصطلحات موضوعية: 0301 basic medicine, medicine.medical_specialty, Bone Density Conservation Agent, Bone disease, 03 medical and health sciences, 0302 clinical medicine, Spinal cord compression, medicine, Humans, Multiple myeloma, Bone Density Conservation Agents, business.industry, medicine.disease, Surgery, Discontinuation, Transplantation, 030104 developmental biology, Zoledronic acid, Denosumab, Oncology, 030220 oncology & carcinogenesis, Practice Guidelines as Topic, Bone Diseases, business, Bone Disease, Multiple Myeloma, medicine.drug, Human

وصف الملف: ELETTRONICO

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::087f0958cccbc7e19db18e9c77a57d23Test
http://www.scopus.com/inward/record.url?scp=85101284824&partnerID=8YFLogxKTest

المؤلفون: Hartmut Goldschmidt, Christoph Heuck, Markus Munder, Edward N. Libby, Maria Teresa Petrucci, Mehmet Turgut, Michele Cavo, Tobias Neff, Ming Qi, Katja Weisel, Robert Kleiman, Mario Boccadoro, Fatih Demirkan, Steven Kuppens, Ihsan Karadogan, Ajai Chari, Pamela L. Clemens, Rajesh Bandekar, Ceri Bygrave, Matthew W Jenner, Niels W.C.J. van de Donk

المساهمون: Chari A., Munder M., Weisel K., Jenner M., Bygrave C., Petrucci M.T., Boccadoro M., Cavo M., van de Donk N.W.C.J., Turgut M., Demirkan F., Karadogan I., Libby E., Kleiman R., Kuppens S., Bandekar R., Neff T., Heuck C., Qi M., Clemens P.L., Goldschmidt H.

المصدر: Advances in Therapy

مصطلحات موضوعية: Monoclonal antibody, Cardiac function curve, medicine.medical_specialty, Phases of clinical research, QT interval, Pharmacokinetic-pharmacodynamic analysis, Electrocardiography, QRS complex, Heart Rate, Daratumumab, Internal medicine, Heart rate, medicine, Humans, Pharmacology (medical), cardiovascular diseases, Smoldering multiple myeloma, Multiple myeloma, Original Research, Pharmacokinetic-pharmacodynamic analysi, business.industry, Antibodies, Monoclonal, General Medicine, medicine.disease, Confidence interval, Cardiology, business, QTc substudy

وصف الملف: STAMPA

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76ce97228f47369191000ad6884b6823Test
https://doi.org/10.1007/s12325-020-01601-wTest

المؤلفون: Elena Zamagni, Cristina Nanni, Luca Dozza, Thomas Carlier, Clément Bailly, Paola Tacchetti, Annibale Versari, Stephane Chauvie, Andrea Gallamini, Barbara Gamberi, Denis Caillot, Francesca Patriarca, Margaret Macro, Mario Boccadoro, Laurent Garderet, Simona Barbato, Stefano Fanti, Aurore Perrot, Francesca Gay, Peter Sonneveld, Lionel Karlin, Michele Cavo, Caroline Bodet-Milin, Philippe Moreau, Françoise Kraeber-Bodéré

المساهمون: Zamagni E., Nanni C., Dozza L., Carlier T., Bailly C., Tacchetti P., Versari A., Chauvie S., Gallamini A., Gamberi B., Caillot D., Patriarca F., Macro M., Boccadoro M., Garderet L., Barbato S., Fanti S., Perrot A., Gay F., Sonneveld P., Karlin L., Cavo M., Bodet-Milin C., Moreau P., Kraeber-Bodere F., Bernardo, Elizabeth, The Institute of Hematology and Oncology L. and A. Seràgnoli [Bologna, Italy], Alma Mater Studiorum Università di Bologna [Bologna] (UNIBO), Policlinico S. Orsola-malpighi, Alma Mater Studiorum Università di Bologna [Bologna] (UNIBO)-Servizio sanitario regionale Emilia-Romagna, Nuclear Oncology (CRCINA-ÉQUIPE 13), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Università degli Studi di Modena e Reggio Emilia = University of Modena and Reggio Emilia (UNIMORE), Santa Croce e Carle Hospital [Cuneo, Italy], Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA), Service d'Hématologie Clinique (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Università degli Studi di Udine - University of Udine [Italie], Laboratoire d'Hématologie Biologique [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Università degli studi di Torino = University of Turin (UNITO), Service d'Hématologie clinique [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Erasmus University Medical Center [Rotterdam] (Erasmus MC), Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service d'Hématologie [Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Università degli Studi di Modena e Reggio Emilia, Università degli studi di Torino (UNITO), Hematology

المصدر: Journal of Clinical Oncology
Journal of Clinical Oncology, 2020, 38, Online ahead of print. ⟨10.1200/JCO.20.00386⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2020, 38, Online ahead of print. ⟨10.1200/JCO.20.00386⟩
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(2), 116-125

مصطلحات موضوعية: Cancer Research, [SDV.CAN]Life Sciences [q-bio]/Cancer, Computed tomography, Newly diagnosed, 18F-Fluorodeoxyglucose, FDG, positron emission tomography, PET, computed tomography, CT, minimal residual disease, multiple myeloma, 03 medical and health sciences, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Deauville Criteria, 18 F-FDG-PET/CT, Medicine, Multiple myeloma, Complete response, 18F-FDG-PET/C, Multiple Myeloma, medicine.diagnostic_test, business.industry, medicine.disease, Standard technique, Minimal residual disease, Oncology, Positron emission tomography, 030220 oncology & carcinogenesis, Fdg pet ct, 18F-FDG, myeloma, Deauville, Nuclear medicine, business, 030215 immunology

وصف الملف: STAMPA; application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d330feb2ab88afd3cc0d9d8d8558443Test
https://doi.org/10.1200/jco.20.00386Test

المؤلفون: Jacopo Nanni, Cristina Papayannidis, Antonio Curti, Francesco Barbato, Stefania Paolini, Sarah Parisi, Michele Cavo, Francesca Bonifazi, Mario Arpinati, Gianluca Cristiano, Giovanni Marconi, Chiara Sartor

المساهمون: Cristiano G., Nanni J., Sartor C., Parisi S., Marconi G., Barbato F., Arpinati M., Bonifazi F., Curti A., Cavo M., Paolini S., Papayannidis C.

المصدر: Acta Haematologica. 144:688-692

مصطلحات موضوعية: Male, Oncology, medicine.medical_specialty, medicine.medical_treatment, Fusion Proteins, bcr-abl, Protein Kinase Inhibitor, Chromosomal translocation, Hematopoietic stem cell transplantation, Philadelphia chromosome, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, chemistry.chemical_compound, Bone Marrow, Positron Emission Tomography Computed Tomography, hemic and lymphatic diseases, Internal medicine, Medicine, Imidazole, Chemotherapy, Acute leukemia, business.industry, Ponatinib, Myeloid leukemia, Hematology, General Medicine, Middle Aged, medicine.disease, Treatment Outcome, chemistry, Nelarabine, Pyridazine, business, T-cell acute lymphoblastic leukemia, Human, medicine.drug

وصف الملف: STAMPA

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9817e9a4d94ebcf35ffc08bcc79cc94eTest
https://doi.org/10.1159/000516003Test

المؤلفون: Fausto Castagnetti, Simona Sica, Cristina Papayannidis, Antonio Percesepe, Monica Crugnola, Gabriele Gugliotta, Michele Cavo, Mariella D'Adda, Massimiliano Bonifacio, Federica Sorà, Gianantonio Rosti, Michele Baccarani, Caterina De Benedittis, Simona Soverini, Isabella Capodanno, Giovanni Martinelli, Luana Bavaro, Margherita Martelli, Patrizia Pregno, Flavio Mignone, Alessandra Iurlo, Francesca Lunghi, Francesco Albano, Sara Galimberti

المساهمون: Soverini S., Martelli M., Bavaro L., De Benedittis C., Sica S., Sora F., Iurlo A., Bonifacio M., Pregno P., Galimberti S., Lunghi F., Albano F., D'Adda M., Crugnola M., Capodanno I., Castagnetti F., Gugliotta G., Papayannidis C., Rosti G., Percesepe A., Mignone F., Baccarani M., Martinelli G., Cavo M.

المصدر: Leukemia. 35:2102-2107

مصطلحات موضوعية: Cancer Research, medicine.drug_class, bcr-abl, Mutant, Fusion Proteins, bcr-abl, Drug Resistance, Philadelphia chromosome, Tyrosine-kinase inhibitor, Bcr abl1, Protein-Tyrosine Kinases, Prevalence, medicine, Humans, Philadelphia Chromosome, Protein Kinase Inhibitors, Leukemia, Philadelphia Chromosome Positive, business.industry, High-Throughput Nucleotide Sequencing, Fusion Proteins, Hematology, medicine.disease, Molecular biology, Oncology, Drug Resistance, Neoplasm, Neoplasm, business, BCR-ABL1, tyrosine kinase inhibitor resistance, Philadelphia chromosome-positive leukemia

وصف الملف: ELETTRONICO

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6b2a53206e09065642f61be47fa6648Test
https://doi.org/10.1038/s41375-020-01098-wTest